Clinical Trial Update: Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating blinatumomab in combination with HLA-mismatched cellular therapy for relapsed/refractory CD19+ B-cell acute lymphoblastic leukemia ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• HLA-mismatched cellular therapy

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult | Phase 1 | Status: COMPLETED